Pancreatic Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Pancreatic Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb

[Nevada, United States] - DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Pancreatic Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Pancreatic Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Pancreatic Cancer Market Report:
• The Pancreatic Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: AstraZeneca announced the results of their Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation.
• In October, 2024: ImmunityBio, Inc. announced the results of their Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
• In October, 2024: Trishula Therapeutics, Inc. announced an Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma
• In September, 2024: Bold Therapeutics, Inc. announced the results of their Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumors.
• Key Pancreatic Cancer Companies are as follows: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb
• Key Pancreatic Cancer Therapies are as follow: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab)m, Mitazalimab (ADC-1013), Elraglusib (9 ING 41), Rucaparib, BOLD-100, ABTL0812, Folfirinox, CT041, Demcizumab, Abraxane, gemcitabine, Lenalidomide Gemcitabine, NovoTTF-200T, Azeliragon, RX-3117
• Launching multiple stage Pancreatic Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Pancreatic Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Pancreatic Cancer Overview:
Pancreatic cancer, known for its aggressiveness, is typically diagnosed at advanced stages, with the majority of patients falling within the age range of 65 to 74 years. Common symptoms of pancreatic cancer include abdominal or back pain, jaundice, weight loss, loss of appetite, fatigue, and digestive problems. However, majority of patients remain asymptomatic until they progress to advanced stage

Pancreatic Cancer Epidemiology Segmentation:
The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Pancreatic Cancer Total Incident Cases in the US
• Pancreatic Cancer Total Incident Cases by Type in the US
• Pancreatic Cancer Total Treated Cases by Line of Therapy in the US
• Pancreatic Cancer Total Incident Cases by Molecular Alterations

For more information about Pancreatic Cancer companies working in the treatment market, visit https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Pancreatic Cancer Market Insights
Pancreatic cancer ranks among the most prevalent cancers with a high mortality rate. Surgical intervention stands out as the optimal treatment for localized or regional cases. However, chemotherapy is the preferred pharmaceutical option across all stages of pancreatic cancer. Additionally, targeted therapies such as LYNPARZA for BRCA mutations, VITRAKVI and ROZLYTREK for NTRK gene expression in solid tumors, and KEYTRUDA for solid tumor patients with microsatellite instability-high expression have been utilized alongside traditional treatments.

Pancreatic Cancer Drugs Uptake
• Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
• SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Pancreatic Cancer Therapies and Key Companies:
• LYNPARZA (olaparib): AstraZeneca
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Vitrakvi: Bayer
• Mitazalimab (ADC-1013): Alligator Bioscience
• Elraglusib (9 ING 41): Actuate Therapeutics
• Rucaparib: pharmaand GmbH
• BOLD-100: Bold Therapeutics, Inc.
• ABTL0812, Folfirinox: Ability Pharmaceuticals SL
• CT041: CARsgen Therapeutics Co., Ltd.
• Demcizumab, Abraxane, gemcitabine: OncoMed Pharmaceuticals, Inc.
• Lenalidomide Gemcitabine: SCRI Development Innovations, LLC
• IOA-289: iOnctura
• NovoTTF-200T: NovoCure Ltd.
• Azeliragon: Cantex Pharmaceuticals
• RX-3117: Processa Pharmaceuticals

Pancreatic Cancer Epidemiology:
Pancreatic cancer remains one of the most lethal cancers worldwide, with an extremely poor prognosis. The disease is often diagnosed at a late stage, limiting treatment options and leading to low survival rates. This article presents an overview of the latest epidemiology, key drugs, and their uptake, along with some of the emerging therapies in the pipeline for pancreatic cancer. n 2023, there were approximately 495,000 new cases of pancreatic cancer globally, accounting for around 2.6% of all cancer cases. The incidence is slightly higher in men than in women. As pancreatic cancer is often diagnosed late, the 5-year prevalence remains low, with an estimated 0.7% of cancer survivors living with this condition.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Pancreatic Cancer Market Drivers:
• Combination chemotherapy has provided an important option for patients with advanced and metastatic disease, enabling short-lived partial remissions or stable disease in newly diagnosed patients.
• Identification of patients with targetable germline and somatic alterations and integration of routine germline and somatic testing in daily practice.

Pancreatic Cancer Market Barriers:
• Chemotherapy, which is the current standard of care in this disease, can cause significant side effects, impacting patients' quality of life.
• Pancreatic cancer is often diagnosed at advanced stages due to the lack of effective screening methods, resulting in limited treatment options and poorer prognosis.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Pancreatic Cancer Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb
• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab)m, Mitazalimab (ADC-1013), Elraglusib (9 ING 41), Rucaparib, BOLD-100, ABTL0812, Folfirinox, CT041, Demcizumab, Abraxane, gemcitabine, Lenalidomide Gemcitabine, NovoTTF-200T, Azeliragon, RX-3117
• Pancreatic Cancer Therapeutic Assessment: Current marketed and emerging therapies
• Pancreatic Cancer Market Dynamics: Pancreatic Cancer Market drivers and Pancreatic Cancer barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pancreatic Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Pancreatic Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Pancreatic Cancer-Market Overview at a Glance
4. Executive Summary of Pancreatic Cancer
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Pancreatic Cancer: Seven Major Market Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.